Mesenchymal stem or stromal cells (MSCs) are identified as sources of pluripotent stem cells with varying degrees of plasticity. Endothelial progenitor cells (EPCs) originate from either bone marrow (BM) or peripheral blood and can mature into cells that line the lumen of blood vessels. MSC and EPC therapies exhibit promising results in a variety of diseases. The current study described the simultaneous isolation of EPCs and MSCs from murine BM using a straightforward approach. The method is based on differences in attachment time and trypsin sensitivity of MSCs and EPCs. The proposed method revealed characteristics of isolated cells. Isolated MSCs were positive for cell surface markers, cluster of differentiation (CD)29, CD44 and stem cell antigen-1 (Sca-1), and negative for hematopoietic surface markers, CD45 and CD11b. Isolated EPCs were positive for Sca-1 and vascular endothelial growth factor receptor 2 and CD133. The results indicate that the proposed method ensured simultaneous isolation of homogenous populations of MSCs and EPCs from murine BM.
CITATION STYLE
Wang, X., Zhao, Z., Zhang, H., Hou, J., Feng, W., Zhang, M., … Wu, X. (2018). Simultaneous isolation of mesenchymal stem cells and endothelial progenitor cells derived from murine bone marrow. Experimental and Therapeutic Medicine, 16(6), 5171–5177. https://doi.org/10.3892/etm.2018.6844
Mendeley helps you to discover research relevant for your work.